Search
BNT162B2 Omicron (LP.8.1)
go.drugbank.com/drugs/DB23337ApprovedBNT162B2 Omicron (LP.8.1) is the active ingredient in the 2025-2026 formulation of Pfizer and BioNTech's Comirnaty mRNA vaccine for COVID-19. … [L53723] It encodes the spike protein from the Omicron LP.8.1 subvariant of SARS-CoV-2.[L53723] The 2025-2026 formulation of Pfizer-BioNTech's Comirnaty was approved by the US FDA in August 2025.
Iomeprol
go.drugbank.com/drugs/DB11705ApprovedInvestigationalIomeprol is a tri-iodinated, non-ionic radiographic contrast agent for intraarterial or intravenous use. … [A265090,A265095] Iomeprol first appeared in the market in 1994 [A265095] and is currently used in various diagnostic processes involving x-ray imaging and computed tomography (CT) scans.[L52260]
Synonyms: N,N'-BIS(2,3-DIHYDROXYPROPYL)-2,4,6-TRIIODO-5-(N-METHYLGLYCOLAMIDO)ISOPHTHALAMIDE, 1,3-BENZENEDICARBOXAMIDE, N,N'-BIS(2,3-DIHYDROXYPROPYL)-5-((HYDROXYACETYL)METHYLAMINO)-2,4,6-TRIIODO-Categories: Compounds used in a research, industrial, or household setting, X-Ray Contrast Media, IodinatedEtryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnIn the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was … In 1993, the US Drug Enforcement Administration added αET to Schedule I of its Schedules of Controlled Substances, after an increasing incidence of its use as a recreational drug in the 1980's.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesChlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnChlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). … Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33).
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaNiclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … They are an even greater problem in domestic animals. Niclosamide, once marketed in the US under the brand name Niclocide, was voluntarily withdrawn from market by Bayer in 1996.[L11860]
Categories: Compounds used in a research, industrial, or household settingPrucalopride
go.drugbank.com/drugs/DB06480ApprovedInvestigational[A40254] Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009,[A40250] in Canada on December 7, 2011 and by the FDA on December 17, 2018.[L4880] … [A37348] The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies.
Categories: Drugs for ConstipationButabarbital
go.drugbank.com/drugs/DB00237ApprovedIllicitWithdrawnButabarbital, or Butisol, is a fast onset barbiturate with short duration of action compared to other barbiturates. … [A201977,L13613] This makes butabarbital a useful drug for treating severe insomnia and pre-operative anxiety.
International brands: Sarisol No. 2Sulfapyridine
go.drugbank.com/drugs/DB00891ApprovedWithdrawnAntibacterial, potentially toxic, and previously used to treat certain skin diseases. No longer prescribed.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseSynonyms: N-2-Pyridylsulfanilamide, N(1)-PyridylsulfanilamideLepirudin
go.drugbank.com/drugs/DB00001ApprovedWithdrawn[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine … at position 1 (N-terminal end).
Synonyms: R-hirudinBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigationalABL ratio on an international scale, with bosutinib treatment. … [A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy.